6. May 2026 | B2B, B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
How can complex medical knowledge be communicated in a way that is not only understood, but also applied in everyday life? This question concerns pharmaceutical companies as well as medical affairs teams and providers of digital health solutions. According to the...
1. Apr 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
Randomized phase III trials are the gold standard of evidence-based drug development. They provide robust data on efficacy and safety and form the basis for regulatory decisions. However, with market approval, a new phase of evidence generation begins: the real-world...
4. Mar 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
What Insights Digital Real-World Data Provide and Where Their Limits Lie Digital therapy companions are increasingly being discussed in the pharmaceutical industry as a potential source of patient insights. At the same time, it often remains unclear what kind of...
